News | Breast Imaging | September 16, 2015

New KLAS Research report analyzes impact of 3-D tomosynthesis on breast imaging, how the market is changing

KLAS, women's imaging, 3-D tomosynthesis, breast imaging

September 16, 2015 — 3-D tomosynthesis is the latest technology to provide clearer images during screening and diagnostic procedures; however, it has not always been widely available. Hologic was the only vendor with U.S. Food and Drug Administration (FDA) approval until April of this year, when Siemens received the much-awaited green light to sell their product in the United States. In the KLAS report Women's Imaging 2015: Are New Technologies Delivering Promised Benefits?, data shows Hologic is still dominating the 3-D tomosynthesis marketplace but is facing competition from Siemens and GE. Now approved, Siemens did not waste any time upgrading their systems, and providers are responding positively. GE is not receiving the same response from users because their 3-D system is lagging due to implementation delays. 

The annual report finds Phillips equipment still provides the strongest image quality for general ultrasound. However, Toshiba receives the highest overall satisfaction score due to their engaged support and adequate image quality and workflow. Siemens and GE users acknowledge the strength and quality of ultrasound images provided by their systems. Siemens and GE are also starting to expand their automated whole breast ultrasound offering, which could potentially be the next new technology that changes the shape of the industry.

"Patients are knowledgeable about women's imaging and are seeking out healthcare organizations that use top-performing equipment for their procedures," said Research Director Monique Rasband. "Patient satisfaction is driving industry innovation and leading organizations to proactively inform the public now about their updated imaging technology."

For more information: www.klasresearch.com


Additional Content

News | Women's Health

Oct. 29, 2026 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive ...

Time October 30, 2026
arrow
News | Radiopharmaceuticals and Tracers

Oct. 19, 2026 — Nuclidium AG, a clinical-stage radiopharmaceutical company, and NorthStar Medical Technologies, a global ...

Time October 19, 2026
arrow
News | Women's Health

Oct. 15, 2026— SimBioSys has announced U.S. Food and Drug Administration (FDA) 510(k) clearance of TumorSight Risk, its ...

Time October 19, 2026
arrow
News | Ultrasound Women's Health

Sept. 29, 2026 — A research team at the University of Virginia (UVA) led by Timothy Bullock, PhD, has published results ...

Time September 30, 2026
arrow
News | Women's Health

Sept. 1, 2026 — On Sept. 24, 2026 at 1 p.m. EDT, Siemens Healthineers will present a webinar on "Advancing Women's ...

Time September 03, 2026
arrow
Subscribe Now